Address: Tour Franklin
100/101 Quartier Boieldieu
La Défense 8
Tour Franklin 100/101 La Défense 8 Quartier Boieldieu 92042 Paris la Défense Cedex,France
Tel: +33 (01) 70 36 03 00
Web: https://www.cipclub.org/Referentiel/
CIP, in accordance with the 1901 French law of associations, contributes to improved circulation of products and information relating to the Public Healthcare System. It works with manufacturers, pharmacists in hospitals and offices, agents, distributors and other representative organisations.
Monica Bettencourt-Dias of the Gulbenkian Institute for Science highlights the IGC’s pioneering role in biological sciences, supporting scientists and innovators who have significantly contributed to the field globally for over…
MARBIO, a new vaccine manufacturing joint venture in Morocco, is the result of a partnership between the BAB banking consortium (Bank of Africa, Banque Centrale Populaire, and Attijariwafa Bank), Swedish…
Leveraging his 24-year career in Big Pharma, Howard Lin recently moved to set up healthcare and life science consultancy CL Consultancy in Hong Kong. Lin examines the opportunities and challenges…
Thomas Eldered, CEO of Sweden’s largest CDMO Recipharm, founded the company together with his business partner in 1995. Since becoming a public company in 2014, he highlights how this changed…
Carlos Ceinos, president of Puerto Rican service provider Principia, highlights how his previous experience in big pharma helped him to successfully establish his business, dedicated to providing automation and IT…
Oscar Gaspar, VP of the Confederation of Portuguese Industry (CIP), president of the Portuguese Association of Private Hospitalization and former secretary of state for health (2009-2011), provides an informative insight…
Umang Vohra, managing director and global CEO of Indian pharma giant Cipla, discusses the company’s ambition to grow in both the domestic and emerging markets as well as the opportunities…
Sasho Ganov, general manager at BB–NCIPD (BulBio), explains the role of the company in the national health system as the only state-owned enterprise in Bulgaria as well as shares his…
Anant Atal, head of Latin America for Cipla, discusses how the establishment of offices in Colombia was facilitated by its longstanding history in the country, the multiple initiatives the company…
The Country Head Commercial Business of Cipla Czech Republic reviews the challenges faced since Cipla began Czech operations two years ago, the company’s expertise in the respiratory segment, and how…
Giorgio Bruno, CEO of Recipharm Italy, gives an insight into the success factors of the CDMO, discusses the recent acquisition of Mitim, and explains how this acquisition helps Recipharm not…
Tania Zulu Holt, Associate Principal at McKinsey & Company elaborates on the current pressures on the South African healthcare system, discusses the importance of innovation and emphasizes the need for…
IMS Health helps clients reach the top of the mountain by providing them with the necessary intelligence to take actionable steps. Manuel Voll, Senior Principal for Northern Europe shares his…
The phasing out of fiscal incentives in 2006 has impacted the Puerto Rican economy as well as the life science arena. The president of DDD Group, a company offering fully…
IMS’s top consultant in Turkey discusses the common pattern that companies in Turkey have and must follow to adapt to today’s market, and the importance of heeding market signals, such…
Raul Manlapig, Principal Managing Director of Arup, Philippines, talks about the current rapid growth of the country’s economy, how the company’s sustained presence in many countries around the world provides…
A lot of the opportunities and challenges in the pharma and healthcare sector of Romania depend on the overall Romanian business environment in the first place. How would you assess…
The French President declared that he intended to make France the most welcoming and attractive place for the healthcare industry. Do you think this is possible? Can France be the…
What has been the contribution of the LRU reform and specifically what has the Creation of Research Centers and Higher Education (PRES) done to establish universities back at the heart…
What has been the contribution of the LRU reform and specifically what has the Creation of Research Centers and Higher Education (PRES) done to establish universities back at the heart…
Can you highlight some of the more recent milestones for Stallergenes? Stallergenes has been successful over recent years for several reasons, the first of which is the growth of the…
As Quintiles is present in all major pharmaceutical markets worldwide, what’s the relevance of the French affiliate and what role it plays inside such a globalized organization? France is important…
When we met your Italian colleague, he noted that they had tripled their turnover in a five year period. You haven’t done badly yourself in the relatively short period of…
Biogaran was an initiative from Servier in the mid 1990s before there was even a generic pharmaceutical market in France. Could you speak of your history and of the origins…
Janssen-Cilag is involved in not only selling its products in France but research and production as well. As France is a leading subsidiary, can you speak to the importance of…
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from…
This interview was conducted with Jacques de Chilly and Theirry de Lumley of Aderly hereafter referred to as J.C. and T.L. respectively. Aderly was founded in 1974 in order to…
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
CIP and GERS have very unique relationships with the pharmaceutical industry. Could you elaborate on the role of these two bodies? Club Inter-pharmaceutique (CIP) is a professional association created in…
As a majority of our readers are American that may be used to a different model of clusters can you explain the unique characteristics of the pôles de compétitivité? The…
See our Cookie Privacy Policy Here
